RESEARCH TRIANGLE PARK – Raleigh-based Merz North America has received approval from the U.S. Food and Drug Administration to market a treatment for blepharospasm, or involuntary blinking, in adults.

Dear Doctors: I’ve recently been diagnosed with benign essential blepharospasm. Would you please explain what this is? How serious is it? Does it spread? I know it’s not deadly, but I’ve read that it ...

RALEIGH, N.C.--(BUSINESS WIRE)--Merz Americas announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XEOMIN ® ...

Tardive Dyskinesia is associated with certain prescription medications used to treat mental health or gastrointestinal conditions, and affects a broad range of people. It is characterized by mild to ...

Tardive Dyskinesia or TD is associated with certain prescription medications used to treat mental health or gastrointestinal conditions, and affects a broad range of people. It is characterized by ...